Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment

  • Authors:
    • Eleftheria Hatzimichael
    • Konstantinos Lagos
    • Amalia Vassou
    • Dora Gougopoulou
    • Alexandra Papoudou‑Bai
    • Evangelos Briasoulis
  • View Affiliations

  • Published online on: April 20, 2016     https://doi.org/10.3892/mco.2016.866
  • Pages: 23-26
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Loss of a section of the long arm of chromosome 5, as a sole cytogenetic abnormality, characterizes a rare type of myelodysplastic syndrome [del(5q) MDS] and the co‑existence of the JAK2 V617F mutation occurs in a small subset of these cases. Patients with isolated del(5q) MDS have a relatively favorable prognosis, with transformation to acute myeloid leukemia occurring in <10%, and their disease responds well to lenalidomide. However the optimal therapeutic approach for patients with del(5q) MDS in coexistence with the JAK2 V617F mutation, which is common to myeloproliferative neoplasms, remains to be elucidated. The present study reports a 77‑year‑old, transfusion-dependent female patient diagnosed with del(5q) MDS and a concomitant JAK2 V617F mutation. The patient was started on 10 mg lenalidomide daily for 21 days in a 28 day‑cycle and within the first month of treatment, the patient became transfusion‑independent. The only toxicity observed was grade 3 neutropenia, which was managed with transient treatment discontinuation and dose reduction on restart (5 mg). The patient achieved a complete cytogenetic and molecular response (normal karyotype and undetected JAK2 V617F mutation) within 6 months of treatment. However, 12 months post treatment initiation and while on hematological, cytogenetic and molecular response, the patient was unwilling to continue on treatment and lenalidomide was discontinued. The patient remains in hematological response, which lasts for >5 years despite treatment discontinuation. The present case highlights the coexistence of the JAK2 V617F mutation in del(5q) MDS and suggests that lenalidomide treatment is beneficial and effective for these patients, leading to complete hematological, cytogenetic and molecular response. Hematological response may be sustained for long periods of time, even following the discontinuation of the treatment.
View Figures
View References

Related Articles

Journal Cover

July 2016
Volume 5 Issue 1

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Hatzimichael, E., Lagos, K., Vassou, A., Gougopoulou, D., Papoudou‑Bai, A., & Briasoulis, E. (2016). Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment. Molecular and Clinical Oncology, 5, 23-26. https://doi.org/10.3892/mco.2016.866
MLA
Hatzimichael, E., Lagos, K., Vassou, A., Gougopoulou, D., Papoudou‑Bai, A., Briasoulis, E."Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment". Molecular and Clinical Oncology 5.1 (2016): 23-26.
Chicago
Hatzimichael, E., Lagos, K., Vassou, A., Gougopoulou, D., Papoudou‑Bai, A., Briasoulis, E."Durable response to lenalidomide in a patient with myelodysplastic syndrome associated with isolated 5q deletion and JAK2 V617F mutation despite discontinuation of treatment". Molecular and Clinical Oncology 5, no. 1 (2016): 23-26. https://doi.org/10.3892/mco.2016.866